Decoy Therapeutics Regains Nasdaq Compliance After Reverse Split

End of Quarter Sale - 50% Off TipRanksUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks Decoy Therapeutics ( (DCOY) ) has shared an announcement. Decoy Therapeutics has regained compliance with Nasdaq’s minimum bid price requirement after a period of deficiency that began with a notice on December 31, 2025, when its shares traded below $1.00 for 30 consecutive business days. Following a February 6, 2026 hearing with a Nasdaq panel, the company executed a reverse stock split effective March 6, 2026, leading to a closing bid of $7.47 on March 20, 2026 and demonstrating at least ten consecutive days above the $1.00 threshold. On March 31, 2026, Nasdaq formally notified Decoy that it was again in compliance with Listing Rule 5550(a)(2) and all other continued listing standards for the Nasdaq Capital Market, securing its listing status. However, the company will remain under a Mandatory Panel Monitor until March 31, 2027, meaning any renewed breach of the bid-price rule during this period could trigger an automatic delisting determination, underscoring ongoing listing risk for shareholders. The most recent analyst rating on (DCOY) stock is a Hold with a $6.50 price target. To see the full list of analyst forecasts on Decoy Therapeutics stock, see the DCOY Stock Forecast page. Spark’s Take on DCOY Stock According to Spark, TipRanks’ AI Analyst, DCOY is a Neutral. The score is held down primarily by weak financial performance (recurring losses, minimal recent revenue, and ongoing cash burn) and bearish technicals (price below key moving averages with negative MACD). Valuation contributes little due to non-informative P/E and missing dividend yield. To see Spark’s full report on DCOY stock, click here. More about Decoy Therapeutics Decoy Therapeutics, Inc., based in Cambridge, Mass. and Houston, is a Nasdaq-listed biotechnology company focused on developing therapeutics, with its pipeline centered on a lead asset built on its IMP3ACT platform. The company targets serious medical conditions and relies on continued access to capital markets to advance its research and development programs. Average Trading Volume: 190,118 Technical Sentiment Signal: Strong Sell Current Market Cap: $3.36M Find detailed analytics on DCOY stock on TipRanks’ Stock Analysis page.